Document is current
Any future updates will be listed below
-
Authors
Frentzas, Sophia https://orcid.org/0000-0002-6917-9737
Austria Mislang, Anna Rachelle
Lemech, Charlotte
Nagrial, Adnan
Underhill, Craig
Wang, Wenjing https://orcid.org/0009-0002-3329-7421
Wang, Zhongmin Maxwell https://orcid.org/0000-0002-1683-5147
Li, Baiyong
Xia, Yu
Coward, Jermaine I G
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04047290 at ClinicalTrials.govnct04047290 at ClinicalTrials.govDocuments that mention this clinical trial
427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study
https://doi.org/10.1136/jitc-2021-sitc2021.427
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
nct04736823 at ClinicalTrials.govDocuments that mention this clinical trial
427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study
https://doi.org/10.1136/jitc-2021-sitc2021.427
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
nct04900363 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
https://doi.org/10.1200/jco.2023.41.16_suppl.9087
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
nct04870177 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant stereotactic body radiotherapy combined with chemotherapy and Ivonescimab for Chinese luminal-type breast cancer patients: study protocol for a single-arm, open-label, phase II trial
https://doi.org/10.1136/bmjopen-2025-102952
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
nct05184712 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
nct05499390 at ClinicalTrials.govDocuments that mention this clinical trial
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.8508
1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR <sup>+</sup> NSCLC progressed on EGFR-TKI treatment
https://doi.org/10.1136/jitc-2025-sitc2025.1348
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
nct05899608 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
nct05840016 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
Documents that mention this clinical trial
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
-
Funding
Funding for this research was provided by:
Akeso Biopharma, Inc., Zhongshan, China (N/A)
- License Information
